Delayed adverse events in phase I trials of molecularly targeted and cytotoxic agents.

Oncotarget · 2018 · PMC6188052 · PMID 30338038

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

G3 showed a highly significant difference (p-value 0.0033) between CCs and MTAs trials; G4 toxicity also showed a significant difference between CCs and MTAs (p-value 0.01).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.